Literature DB >> 12587045

B-type natriuretic peptide (BNP): can it improve our management of patients with congestive heart failure?

Christian Mueller1, Peter Buser.   

Abstract

Until recently no simple specific test existed for the differentiation of decompensated heart failure from other causes of acute dyspnoea, or to assess the prognosis of patients with severe heart failure or to optimize heart failure therapy in an individual patient. Measurement of B-type natriuretic peptide has become available as an easy-to-per-form bedside test. Several studies have demonstrated it's usefulness in the emergency room to differentiate heart failure from other causes of acute dyspnoea or to guide the complex drug therapy in an individual patient with heart failure. This article gives a short overview on the clinical experience to use BNP-blood levels for the diagnosis and treatment guidance of heart failure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12587045     DOI: 2002/43/smw-10092

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  2 in total

Review 1.  Utility of natriuretic peptide testing in the evaluation and management of acute decompensated heart failure.

Authors:  Jun R Chiong; Geoffrey T Jao; Kirkwood F Adams
Journal:  Heart Fail Rev       Date:  2010-07       Impact factor: 4.214

2.  Transcatheter closure of patent ductus arteriosus: 11 years of clinical experience in Cipto Mangunkusumo Hospital, Jakarta, Indonesia.

Authors:  Mulyadi M Djer; Dimas Dwi Saputro; Sukman Tulus Putra; Nikmah Salamia Idris
Journal:  Pediatr Cardiol       Date:  2015-03-07       Impact factor: 1.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.